Cargando…

A case of multiple metastatic sarcomatoid renal cell carcinoma with complete response to nivolumab

BACKGROUND: Sarcomatoid renal cell carcinoma (SRCC) is associated with poor prognosis. Although there is no standard treatment for SRCC, recent studies have reported the effectiveness of immune checkpoint inhibitors. CASE: An 82‐year‐old Japanese man presented to our hospital with an incidental righ...

Descripción completa

Detalles Bibliográficos
Autores principales: Tomioka, Masayuki, Nakane, Keita, Ozawa, Kaori, Iinuma, Koji, Suzui, Natsuko, Miyazaki, Tatsuhiko, Koie, Takuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8388173/
https://www.ncbi.nlm.nih.gov/pubmed/33656804
http://dx.doi.org/10.1002/cnr2.1356
_version_ 1783742590205558784
author Tomioka, Masayuki
Nakane, Keita
Ozawa, Kaori
Iinuma, Koji
Suzui, Natsuko
Miyazaki, Tatsuhiko
Koie, Takuya
author_facet Tomioka, Masayuki
Nakane, Keita
Ozawa, Kaori
Iinuma, Koji
Suzui, Natsuko
Miyazaki, Tatsuhiko
Koie, Takuya
author_sort Tomioka, Masayuki
collection PubMed
description BACKGROUND: Sarcomatoid renal cell carcinoma (SRCC) is associated with poor prognosis. Although there is no standard treatment for SRCC, recent studies have reported the effectiveness of immune checkpoint inhibitors. CASE: An 82‐year‐old Japanese man presented to our hospital with an incidental right renal tumor. Abdominal computed tomography (CT) showed an exophytic tumor in the right kidney with suspected right iliopsoas muscle invasion. Laparoscopic right radical nephrectomy was performed. Histopathological diagnosis revealed a clear cell RCC with a spindle cell carcinoma component. CT performed 3 months after surgery revealed multiple bilateral lung metastases and local recurrence. Although the patient received tyrosine‐kinase inhibitors for treating multiple metastases, the lung metastases continued to gradually increase, and peritonitis carcinomatosis was observed. Thus, the patient was intravenously administered nivolumab once every 2 weeks. After nivolumab administration, lung metastases, local recurrence, and peritonitis carcinomatosis gradually reduced. After 20 months of nivolumab treatment, the patient achieved a complete response of multiple metastases on CT. CONCLUSION: Nivolumab may be used as a treatment option for sarcomatoid renal cell carcinoma with multiple metastases.
format Online
Article
Text
id pubmed-8388173
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-83881732021-08-31 A case of multiple metastatic sarcomatoid renal cell carcinoma with complete response to nivolumab Tomioka, Masayuki Nakane, Keita Ozawa, Kaori Iinuma, Koji Suzui, Natsuko Miyazaki, Tatsuhiko Koie, Takuya Cancer Rep (Hoboken) Case Reports BACKGROUND: Sarcomatoid renal cell carcinoma (SRCC) is associated with poor prognosis. Although there is no standard treatment for SRCC, recent studies have reported the effectiveness of immune checkpoint inhibitors. CASE: An 82‐year‐old Japanese man presented to our hospital with an incidental right renal tumor. Abdominal computed tomography (CT) showed an exophytic tumor in the right kidney with suspected right iliopsoas muscle invasion. Laparoscopic right radical nephrectomy was performed. Histopathological diagnosis revealed a clear cell RCC with a spindle cell carcinoma component. CT performed 3 months after surgery revealed multiple bilateral lung metastases and local recurrence. Although the patient received tyrosine‐kinase inhibitors for treating multiple metastases, the lung metastases continued to gradually increase, and peritonitis carcinomatosis was observed. Thus, the patient was intravenously administered nivolumab once every 2 weeks. After nivolumab administration, lung metastases, local recurrence, and peritonitis carcinomatosis gradually reduced. After 20 months of nivolumab treatment, the patient achieved a complete response of multiple metastases on CT. CONCLUSION: Nivolumab may be used as a treatment option for sarcomatoid renal cell carcinoma with multiple metastases. John Wiley and Sons Inc. 2021-03-03 /pmc/articles/PMC8388173/ /pubmed/33656804 http://dx.doi.org/10.1002/cnr2.1356 Text en © 2021 The Authors. Cancer Reports published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Tomioka, Masayuki
Nakane, Keita
Ozawa, Kaori
Iinuma, Koji
Suzui, Natsuko
Miyazaki, Tatsuhiko
Koie, Takuya
A case of multiple metastatic sarcomatoid renal cell carcinoma with complete response to nivolumab
title A case of multiple metastatic sarcomatoid renal cell carcinoma with complete response to nivolumab
title_full A case of multiple metastatic sarcomatoid renal cell carcinoma with complete response to nivolumab
title_fullStr A case of multiple metastatic sarcomatoid renal cell carcinoma with complete response to nivolumab
title_full_unstemmed A case of multiple metastatic sarcomatoid renal cell carcinoma with complete response to nivolumab
title_short A case of multiple metastatic sarcomatoid renal cell carcinoma with complete response to nivolumab
title_sort case of multiple metastatic sarcomatoid renal cell carcinoma with complete response to nivolumab
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8388173/
https://www.ncbi.nlm.nih.gov/pubmed/33656804
http://dx.doi.org/10.1002/cnr2.1356
work_keys_str_mv AT tomiokamasayuki acaseofmultiplemetastaticsarcomatoidrenalcellcarcinomawithcompleteresponsetonivolumab
AT nakanekeita acaseofmultiplemetastaticsarcomatoidrenalcellcarcinomawithcompleteresponsetonivolumab
AT ozawakaori acaseofmultiplemetastaticsarcomatoidrenalcellcarcinomawithcompleteresponsetonivolumab
AT iinumakoji acaseofmultiplemetastaticsarcomatoidrenalcellcarcinomawithcompleteresponsetonivolumab
AT suzuinatsuko acaseofmultiplemetastaticsarcomatoidrenalcellcarcinomawithcompleteresponsetonivolumab
AT miyazakitatsuhiko acaseofmultiplemetastaticsarcomatoidrenalcellcarcinomawithcompleteresponsetonivolumab
AT koietakuya acaseofmultiplemetastaticsarcomatoidrenalcellcarcinomawithcompleteresponsetonivolumab
AT tomiokamasayuki caseofmultiplemetastaticsarcomatoidrenalcellcarcinomawithcompleteresponsetonivolumab
AT nakanekeita caseofmultiplemetastaticsarcomatoidrenalcellcarcinomawithcompleteresponsetonivolumab
AT ozawakaori caseofmultiplemetastaticsarcomatoidrenalcellcarcinomawithcompleteresponsetonivolumab
AT iinumakoji caseofmultiplemetastaticsarcomatoidrenalcellcarcinomawithcompleteresponsetonivolumab
AT suzuinatsuko caseofmultiplemetastaticsarcomatoidrenalcellcarcinomawithcompleteresponsetonivolumab
AT miyazakitatsuhiko caseofmultiplemetastaticsarcomatoidrenalcellcarcinomawithcompleteresponsetonivolumab
AT koietakuya caseofmultiplemetastaticsarcomatoidrenalcellcarcinomawithcompleteresponsetonivolumab